Search
Aducanumab
go.drugbank.com/drugs/DB12274ApprovedInvestigationalthe data [A235720] and aducanumab was granted accelerated FDA approval on 7 June 2021. … [A235720] Development of aducanumab was discontinued in March 2019 when two phase 3 clinical trials did not pass futility analysis; however, Biogen sought FDA approval in October 2019 after reanalyzing
Gemtuzumab ozogamicin
go.drugbank.com/drugs/DB00056ApprovedInvestigationalGemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheamicin per mole of antibody [FDA Label]. … Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by FDA as a treatment for patients with CD33-positive AML in first relapse who are 60 years of age or older and who are not considered
Vericiguat
go.drugbank.com/drugs/DB15456ApprovedInvestigational[L31178] Vericiguat was approved by the FDA in January 2021 - developed by Merck under the brand name Verquvo - for use in certain patients with systolic heart failure. … [L31178] Although not the first sGC stimulator to be granted FDA approval ([riociguat] was approved in 2013 for use in pulmonary hypertension),[L3955] vericiguat is unique amongst its peers in that modifications
Faricimab
go.drugbank.com/drugs/DB15303ApprovedInvestigational[L43085] On April 9, 2026, the FDA approved an updated label that extended faricimab treatment for macular edema following retinal vein occlusion (RVO) beyond six months.[L40026] … [A225985, A225990, A225995, A226000, A226005, A226010] Faricimab was approved by the FDA on January 28, 2022, and is currently marketed under the trademark VABYSMO by Genentech, Inc.
Avatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigational[F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure. … [L2932] In July 2025, the FDA expanded approval to include a new pediatric formulation, Doptelet Sprinkle (avatrombopag oral granules), specifically designed for children aged one to less than six years
Categories: Thrombopoietin Receptor AgonistInositol 1,4,5-trisphosphate-gated calcium channel ITPR2
go.drugbank.com/bio_entities/BE0009594TargetHumansInositol 1,4,5-trisphosphate-gated calcium channel that upon inositol 1,4,5-trisphosphate binding transports calcium from the endoplasmic reticulum lumen to cytoplasm. Exists in two states; a long-lived closed state where the channel is ...
Synonyms: IP3 receptor isoform 2, Type 2 InsP3 receptorCaffeine
go.drugbank.com/drugs/DB00201ApprovedInvestigational[T716] The caffeine citrate injection, used for apnea of the premature newborn, was initially approved by the FDA in 1999.
Mixtures: Ara Menstrual CompleteT-cell surface antigen CD2
go.drugbank.com/bio_entities/BE0000719TargetHumansCD2 interacts with lymphocyte function-associated antigen CD58 (LFA-3) and CD48/BCM1 to mediate adhesion between T-cells and other cell types. CD2 is implicated in the triggering of T-cells, the cytoplasmic domain is implicated in the si...
Synonyms: LFA-3 receptor, Rosette receptorInositol 1,4,5-trisphosphate-gated calcium channel ITPR3
go.drugbank.com/bio_entities/BE0009595TargetHumansInositol 1,4,5-trisphosphate-gated calcium channel that, upon 1D-myo-inositol 1,4,5-trisphosphate binding, transports calcium from the endoplasmic reticulum lumen to cytoplasm, thus releasing the intracellular calcium and therefore parti...
Synonyms: IP3 receptor isoform 3, Type 3 InsP3 receptorNicorandil
go.drugbank.com/drugs/DB09220ApprovedInvestigationalWithdrawnIt is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels.